AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games By: MarketWatch August 04, 2017 at 15:08 PM EDT On paper, the newly-approved hepatitis C drug Mavyret is a positive steal. Read More >> Related Stocks: AbbVie Bristol-Myers Squibb Gilead Sciences Johnson & Johnson Merck & Co